Last reviewed · How we verify
Ontak
At a glance
| Generic name | Ontak |
|---|---|
| Also known as | Denileukin Diftitox, DAB 389 IL-2, Denileukin diftitox, DAB389 interleukin-2, DAB389 interleukin-2 immunotoxin |
| Sponsor | The University of Texas Health Science Center at San Antonio |
| Target | Interleukin-2 receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Approved indications
- Primary cutaneous T-cell lymphoma
- Refractory peripheral T-cell lymphoma
Common side effects
Key clinical trials
- A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel (PHASE1, PHASE2)
- HCW9302 (Interleukin-2 Fusion Protein) for Alopecia Areata (PHASE1)
- T-regulatory Cell Depletion with E7777 Combined with Pembrolizumab in Recurrent or Metastatic Solid Tumors (PHASE1, PHASE2)
- A Study of Remitoro in Participants With Recurrent or Refractory Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma (All Case Study)
- Denileukin Diftitox in Treating Patients With Non-Hodgkin's Lymphoma (PHASE2)
- Therapeutic Autologous Lymphocytes, Aldesleukin, and Denileukin Diftitox in Treating Patients With Stage III-IV Melanoma (PHASE1, PHASE2)
- Study of Denileukin Diftitox in Participants With Stage IIIC and Stage IV Melanoma (PHASE2)
- Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ontak CI brief — competitive landscape report
- Ontak updates RSS · CI watch RSS
- The University of Texas Health Science Center at San Antonio portfolio CI